[Ip-health] RESULTS UK welcomes the G20’s renewed commitment to combat drug-resistance

Rachael Crockett rachael.crockett at results.org.uk
Sat Jul 8 08:07:57 PDT 2017


*HAMBURG, 8 July, 2017:* RESULTS UK welcomes the G20’s call for a new R&D
platform to incentivise research and development to tackle drug-resistant
infections, and is delighted that the specific threat of tuberculosis - the
world’s leading infectious killer, accounting for a third of deaths from
drug resistance - has been recognised in the Leaders’ communiqué.

Aaron Oxley, RESULTS UK Executive Director, said: “This year’s G20 Summit
provided the world’s wealthiest nations with an opportunity to reset
efforts to end tuberculosis, the only airborne drug resistant infection,
and curb the rising tide of drug-resistance. This opportunity was seized in
full, and we welcome their commitment to urgently combat drug-resistance
tuberculosis.”

The number of deaths from drug-resistant TB is increasing, at the same time
that global investment into TB research and development is falling. The
current spending on all TB research and development (drugs, diagnostics and
vaccines) is only 33.7% of the $2 billion that is needed. RESULTS UK
applauds the call for a “new international R&D Collaboration Hub to
maximise the impact of existing and new anti-microbial…research
initiatives” outlined in the communiqué and calls on all G20 countries to
back it.

 Addressing the complex market failure for drug resistant infections,
including multi-drug resistant TB, will require innovative mechanisms. This
initiative must address all aspects of the research and development
pipeline, including basic research and pull incentives. RESULTS UK looks
forward to the outcome of the OECD, WHO and relevant experts research into
practical market incentive options in 2018, as directed by the Group of 20.

“The fact that there have been no new first line drugs to treat TB for over
50 years highlights a significant market failure – it is clear that current
market incentives haven’t provided us what we need” said Rachael Crockett,
Policy Advocacy Officer at RESULTS UK and co-chair of the C20 Health
Working Group.

She added: “an innovative mechanism to incentivise research and development
to combat drug-resistant tuberculosis will save trillions of dollars and
millions of lives when the world’s wealthiest nations get behind it”.

The next 12 months present a number of opportunities for global action on
tuberculosis, starting with the Global Ministerial Conference on ending TB
in the sustainable development era in Moscow in November, followed by the
first ever UN High-Level Meeting on Tuberculosis in 2018.

Aaron Oxley concluded: “Developing new tools to tackle tuberculosis is just
one piece of the puzzle. We now urge health ministers attending the Global
Ministerial Conference in Moscow to galvanise political will and action on
TB, ahead of the first UN High-Level Meeting on the disease next year.”



*Notes to the Editor*

For further information, please contact Rachael Crockett on
rachael.crockett at results.org.uk or 07891056651

The German G20 communique can be found here.
<https://www.g20.org/gipfeldokumente/G20-leaders-declaration.pdf>

RESULTS UK is a movement of passionate, committed, everyday people who
together use their voices to influence political decisions that will bring
an end to poverty. For more information please visit www.results.org.uk.



More information about the Ip-health mailing list